Author Archives: Huub Koets

Differences found in lung deposition of extrafine vs non-extrafine triple therapies in patients with COPD using FRI.

This study will be presented at ERS 2019 at a thematic poster session on Monday September 30 between 12.50 pm and 2.40 pm.

Functional Respiratory Imaging evaluated lung deposition patterns of extrafine ICS/LABA/LAMA with a pressurized metered dose inhaler (pMDI) and non-extrafine ICS/LABA/LAMA with a dry powder inhaler (DPI), in patients with stable COPD and moderate to very severe airflow obstruction.

FRI data indicated a higher peripheral lung (small airways) deposition with extrafine triple therapy than with non-extrafine. This may be attributed to the lower Mass Median Aerodynamic Diameter (MMAD) of the extrafine formulation.

Change in airway volume, measured with FRI, differentiates between stable and progressive IPF.

This study will be presented at ERS 2019 at a thematic poster session on Sunday September 29 between 12.50 pm and 2.40 pm. In a retrospective imaging analysis study, FRI ( Functional Respiratory Imaging )compared CT scans of IPF (Ideopathic Pulmonary Fibrosis) patients from two cohorts. 12 treatment-naïve IPF patients were sequentially identified at a… Continue Reading

Fluidda is present at the ERS in Madrid with a booth and seven posters on new reseach with FRI technology.

From  September 28 until October 2, Fluidda will exhibit at the annual conference of the European Respiratory Society in Madrid, Spain. During this conference, Fluidda will present 7 posters on recent scientific research using our proprietary Functional Respiratory imaging (FRI) technology in studies to assess, among others, lung disease progression, differences in lung deposition of comparable… Continue Reading

FLUIDDA donates laptops to emerging countries

FLUIDDA is the leading company in the field of Functional Respiratory imaging (FRI). FLUIDDA develops respiratory solutions to detect lung diseases earlier, assists in the development of more effective drugs and facilitates the choice of optimal treatment. We also combine this with integrity and social and environmental responsibility. Forty-three laptops, previously used for patient training… Continue Reading

Bronchial thermoplasty increases airway volume measured by Functional Respiratory Imaging (FRI)

In a  recently published study (click here for full article)10 patients with unstable, severe asthma were treated with bronchial thermoplasty of the left lung, while the right lung was used as an internal control. Changes in lung structure and function were assessed with Functional Respiratory Imaging (FRI). Significant differences between the treatment and control lungs were… Continue Reading

FLUIDDA attends the International Conference of Medical imaging with Deep Learning

During July 8-10 the International Conference of Medical imaging with Deep Learning takes place in London. The FLUIDDA team, specialised in using advanced A.I. algorithms to extract clinically relevant regional information from medial images, will be present to keep track on the latest developments in this exciting field of research. Continue Reading

FLUIDDA will be present at the Annual Drug Discovery & Development Symposium on Pulmonary Vascular Disease

This year’s symposium will take place in Paris on July 1-2. Each year the meeting brings leading scientists in the fields of pulmonary vascular disease, right heart failure, and clinical trial designs together with the pharmaceutical industry and regulatory authorities to help identify the most promising treatments for future development.  Fluidda is actively involved in clinical… Continue Reading

Jan de Backer, CEO and founder of Fluidda, speaks about the partnership with Materialise at the ATS conference.

De Backer states: “We are very excited and proud to enter into this new phase of partnership with Materialise. We share the vision that the medical field, and particularly respiratory healthcare imaging needs to evolve towards personalized, precision medicine through a value-based healthcare approach. We are confident that advanced imaging techniques, such as our Functional… Continue Reading

Friday June 7: Presentation FLUIDDA on CFD and lung deposition at the ECFS 2019 conference in Liverpool

At the yearly conference of the European Cystic Fibrosis Society which takes place from June 5-8 in liverpool (UK), the CEO and founder of Fluidda, Jan de Backer, will present new data obtained bij Functional Respiratory imaging ( FRI) on deposition patterns of CF-medication in the lung, and it’s clinical impact. The presentation will take… Continue Reading

Jan de Backer, CEO and founder of Fluidda, explains the purpose of the FIGHT-project at the ATS conference.

FIGHT is a non-profit charity project which has been established together with FLUIDDA, focusing on research of the lung health of Californian firefighters. The key purpose of the charity is to examine lung diseases rooting from wildfire smoke exposure, investigate how these diseases can be detected earlier on, and determine how treatment protocols can be… Continue Reading